Nuclear Is Back in a Big Way. Here Are 2 Stocks to Consider.

The article is constructive on the nuclear power industry, highlighting projected global market growth to $41.6 billion in 2026 and $52.6 billion by 2034. BWX Technologies reported 2025 revenue of $3.2 billion and expects $3.7 billion in 2026, while Cameco posted 2025 revenue of $3.4 billion and gross profit of $970 million, both signaling rising demand. It also notes BWX’s acquisition of Precision Components Group and dividend yields of 0.4% for BWX and 0.1% for Cameco.

Analysis

The key incremental signal is not “nuclear is back,” but that the spend is migrating from policy narrative to industrial bottlenecks. BWXT looks better positioned near term because it sits closer to the capacity constraint: if domestic buildout accelerates, the scarce asset is not uranium exposure but qualified manufacturing, components, and regulated production capacity. That makes BWXT the cleaner beneficiary of a multi-year capex cycle, especially if defense, space, and commercial nuclear all compete for the same supply chain.

Cameco is more of a duration trade on fuel-cycle normalization. Its upside depends less on headline reactor enthusiasm and more on whether utilities are forced to lock in long-term uranium contracts at materially higher prices; that dynamic can lag by quarters, then reprice quickly once utilities stop waiting. The risk is that the market is already discounting a strong contracting environment, so any delay in reactor restarts, permitting, or financing can compress the multiple before fundamentals catch up.

The contrarian read is that the market may be overestimating how linear the nuclear trade will be. Small industry size means incremental demand can move earnings sharply, but it also means execution slippage, regulatory delays, and supply-chain congestion have outsized effects; in other words, the path is likely to be lumpy rather than smooth. The higher multiple on CCJ suggests the easy re-rating may already be behind us, while BWXT still has room if investors begin valuing it as critical infrastructure rather than a niche industrial.

Key Decisions for Investors

• Long BWXT on any 5-8% pullback over the next 1-3 months; prefer it over CCJ as a better risk-adjusted way to express the domestic nuclear capacity expansion theme, with a catalyst from order growth / M&A synergies into the next two earnings prints.
• Use a BWXT/CCJ pair trade: long BWXT, short CCJ in roughly equal dollar terms for a 3-6 month horizon; thesis is BWXT’s earnings leverage to manufacturing scarcity versus CCJ’s already-stretched multiple and higher sensitivity to contracting delays.
• For option expression, buy BWXT call spreads 6-9 months out rather than outright stock; the setup is bullish but capped by valuation, so defined-risk upside is preferable if the market starts to re-rate the name as infrastructure.
• Avoid initiating fresh CCJ outright longs at current levels unless uranium spot or long-term contract indicators confirm; if owning, consider trimming into strength and replacing with a small basket of uranium supply chain names with less multiple compression risk.
• Set a tactical alert for any policy/utility announcement that expands U.S. reactor procurement or fuel contracts; those are the fastest catalysts for a 10-20% move in BWXT and a delayed but potentially larger move in CCJ over 6-12 months.